Workflow
Amedisys(AMED)
icon
Search documents
Amedisys Reports Fourth Quarter and Year End 2024 Financial Results
Newsfilter· 2025-02-26 21:30
Core Viewpoint - Amedisys, Inc. reported its financial results for the fourth quarter and full year of 2024, highlighting significant changes in revenue, net income, and operational metrics amid a pending merger with UnitedHealth Group [1][2]. Financial Performance - Net service revenue for Q4 2024 increased by $27.3 million to $598.1 million compared to $570.8 million in Q4 2023 [4]. - For the full year 2024, net service revenue rose by $111.9 million to $2,348.3 million from $2,236.4 million in 2023 [4]. - The company reported a net loss attributable to Amedisys, Inc. of $20.4 million for Q4 2024, which included merger-related expenses of $17.4 million and a non-cash goodwill impairment charge of $48.4 million [4]. - In contrast, the net income attributable to Amedisys, Inc. for Q4 2023 was $19.3 million, which included merger-related expenses of $11.5 million [4]. - Adjusted EBITDA for Q4 2024 was $54.6 million, down from $56.7 million in Q4 2023 [4]. - For the full year 2024, adjusted net income attributable to Amedisys, Inc. was $142.7 million, compared to $140.6 million in 2023 [4]. Operational Metrics - The company experienced a decline in Medicare revenue by 4% in Q4 2024, while non-Medicare revenue increased by 19% [19]. - Total admissions for Q4 2024 rose by 8% to 109,686 compared to 101,809 in Q4 2023 [19]. - The average Medicare revenue per completed episode increased to $3,030 in Q4 2024 from $2,997 in Q4 2023 [19]. Balance Sheet Highlights - As of December 31, 2024, total assets were $2,138.7 million, up from $2,060.2 million in 2023 [14]. - Cash and cash equivalents increased significantly to $303.2 million from $126.5 million in 2023 [14]. - Total liabilities stood at $958.7 million, compared to $940.4 million in 2023 [14]. Segment Information - In the Home Health segment, net service revenue for Q4 2024 was $377.0 million, up from $358.9 million in Q4 2023 [19]. - The Hospice segment reported net service revenue of $212.9 million for Q4 2024, compared to $206.0 million in Q4 2023 [23]. - The High Acuity Care segment generated $8.1 million in net service revenue for Q4 2024, an increase from $5.9 million in Q4 2023 [26].
Amedisys (AMED) Earnings Expected to Grow: Should You Buy?
ZACKS· 2025-02-12 16:06
The market expects Amedisys (AMED) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, ...
Amedisys Honors 47 Employees With Annual Spirit of Excellence Award
Newsfilter· 2025-02-03 11:30
BATON ROUGE, La., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED), a leading provider of home health, hospice and high-acuity care services, has recognized 47 employees with the prestigious Spirit of Excellence Awards, one of the company's highest honors. "Every day, our employees bring warmth, compassion and clinical expertise into the homes of our patients, offering the care they need in the place they most want to be," said Richard Ashworth, President and Chief Executive Officer. "We are p ...
Amedisys Honors 47 Employees With Annual Spirit of Excellence Award
GlobeNewswire· 2025-02-03 11:30
BATON ROUGE, La., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice and high-acuity care services, has recognized 47 employees with the prestigious Spirit of Excellence Awards, one of the company’s highest honors. “Every day, our employees bring warmth, compassion and clinical expertise into the homes of our patients, offering the care they need in the place they most want to be,” said Richard Ashworth, President and Chief Executive Officer. “We are ...
Amedisys, UnitedHealth Group Extend Deadline To Complete $3.3B Merger
Investopedia· 2024-12-27 16:55
Key TakeawaysUnitedHealth Group and Amedisys agreed to extend the deadline to complete their $3.3 billion merger. The deal had been expected to be completed this week, but federal and state regulators moved to block it, and the challenge is currently before a Maryland court.The deal's new deadline is 10 days following the court's ruling or Dec. 31, 2025, whichever comes first. UnitedHealth Group (UNH) and Amedisys (AMED) agreed to extend the deadline to complete their $3.3 billion merger, after the U.S. Dep ...
Amedisys and UnitedHealth Extend Merger Deadline - What's Going On?
Benzinga· 2024-12-27 16:11
Amedisys Inc AMED shares are trading higher on Friday after the company announced it extended its merger deadline with UnitedHealth Group Incorporated UNH.In an exchange filing, the companies entered into a waiver agreement, further advancing their merger deal, originally announced on June 26, 2023.Under the terms of the agreement, Merger Sub, a wholly owned subsidiary of UnitedHealth, will merge with Amedisys, with Amedisys continuing to operate as a subsidiary of UnitedHealth Group.The companies have agre ...
AMED Q3 Earnings and Revenues Miss, Margins Dip, Stock Falls
ZACKS· 2024-11-11 14:40
Core Insights - Amedisys, Inc. reported adjusted earnings per share (EPS) of $1.00 for Q3 2024, a 2% increase year over year, but missed the Zacks Consensus Estimate by 12.3% [1] - The company's net service revenues reached $587.7 million, reflecting a 5.7% year-over-year growth, but also fell short of the Zacks Consensus Estimate by 0.1% [3] - The impending merger with UnitedHealth Group's Optum is expected to close in the second half of 2024, aiming to enhance value-based care delivery [10] Financial Performance - The GAAP EPS was reported at 51 cents, down from 79 cents in the same period of 2023 [1] - Gross profit increased by 2.2% to $250.1 million, while gross margin decreased by 142 basis points to 42.6% due to an 8.3% rise in service costs [6] - Selling, General and Administrative (SG&A) expenses rose by 4.4% to $134.8 million, while adjusted operating profit was $58.5 million, a 0.4% increase year over year [7] Segment Analysis - Home Health division revenues totaled $372.1 million, up 5.8% year over year, with Medicare revenues decreasing by 2.7% to $212.1 million, while non-Medicare revenues increased by 19.7% to $160 million [4] - Hospice division revenues were $207.9 million, a 3.8% increase year over year, with Medicare revenues rising by 4.7% to $197.8 million, but non-Medicare revenues fell by 10.6% to $10.1 million [4] - The High Acuity Care segment reported revenues of $7.7 million, up from $4.4 million in the previous year [5] Liquidity and Cash Position - Amedisys ended Q3 2024 with cash and cash equivalents of $245.4 million, an increase from $149.9 million at the end of Q2 2024 [8] - Cumulative net cash provided by operating activities was $151.4 million, compared to $76.9 million a year ago [9] Merger Developments - The merger with UnitedHealth Group involves the sale of certain Amedisys home health care centers and UnitedHealth Group care centers to VCG Luna, LLC, contingent on the merger's successful closing [11]
Amedisys(AMED) - 2024 Q3 - Quarterly Report
2024-11-07 13:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share AMED The NASDAQ Global Select Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE ...
Amedisys (AMED) Reports Q3 Earnings: What Key Metrics Have to Say
ZACKS· 2024-11-07 03:30
For the quarter ended September 2024, Amedisys (AMED) reported revenue of $587.67 million, up 5.7% over the same period last year. EPS came in at $1.00, compared to $0.98 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $588.13 million, representing a surprise of -0.08%. The company delivered an EPS surprise of -12.28%, with the consensus EPS estimate being $1.14.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and ho ...
Amedisys (AMED) Q3 Earnings and Revenues Lag Estimates
ZACKS· 2024-11-07 01:11
Amedisys (AMED) came out with quarterly earnings of $1 per share, missing the Zacks Consensus Estimate of $1.14 per share. This compares to earnings of $0.98 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -12.28%. A quarter ago, it was expected that this home health care and hospice services provider would post earnings of $1.22 per share when it actually produced earnings of $1.32, delivering a surprise of 8.20%.Over the las ...